Memorial Sloan-Kettering Cancer Center: Commack

Commack, New York 11725

6 studies enrolling now · 42 studies all time

What they study most

ATM Gene Mutation, Adenocarcinoma of the Prostate, Adenocarcinoma, Pancreatic Ductal, Adjuvant, Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Advanced Breast Cancer, Advanced Gastric Cancer, Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Anaplastic Large-Cell Lymphoma, Anterior or Posterior Pelvic Exenteration, BRIP1 Gene Mutation, Bladder Cancer

Studies at this site

• Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma — Recruiting now
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC — Recruiting now
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. — Recruiting now
• A Study of Sacituzumab Govitecan in People With Mesothelioma — Recruiting now
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease — Recruiting now
• Collection of Information to Better Understand Young Onset Colorectal Cancer — Recruiting now
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) — Running, not enrolling
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer — Completed
• A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer — Running, not enrolling
• A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE — Stopped early
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer — Stopped early
• A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE — Stopped early
• Prospective Registry of Multiplex Testing (PROMPT) — Running, not enrolling
• RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer — Running, not enrolling
• Olaparib In Metastatic Breast Cancer — Running, not enrolling
• A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma — Running, not enrolling
• A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors — Running, not enrolling
• Cisplatin vs Paclitaxel for Triple Negative Breast Cancer — Completed
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Completed
• A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera — Running, not enrolling
• Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy — Stopped early
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma — Completed
• Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma — Completed
• Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer — Completed
• Quality of Life in Patients Undergoing Total Pelvic Exenteration — Completed
• A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) — Completed
• Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies — Status unconfirmed
• Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer — Completed
• Acupuncture for Symptoms of Nerve Damage — Completed
• A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy — Completed
• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer — Status unconfirmed
• Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma — Completed
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma — Completed
• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer — Completed
• TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer — Completed
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas — Completed
• Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) — Stopped early
• Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation — Completed
• A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations — Stopped early